Geminin as an Emerging Anticancer Drug Target

Heat shock protein 70 (hsp70) as an emerging drug target.

Dual-Target Anticancer Drug Candidates: Rational Design and Simulation Studies

This study aims to design some dual-target anticancer candidates, capable to act as an alkylating agent as well as a thymidylate synthase (TS) inhibitor. The designed scaffold is a combination of nucleobase, amino acid and aziridine structures. The candidates are docked into TS and three DNA double strand structures and evaluated based on their binding interaction energies and ligand efficienci...

Eribulin: rediscovering tubulin as an anticancer target.

Eribulin mesylate (E7389) is a synthetic analog of the marine macrolide halichondrin B, which acts as a novel microtubule modulator with a distinct mechanism of action. Two eribulin mesylate phase 1 studies exploring weekly and 3-weekly schedules are reported in this issue. These trials show linear pharmacokinetics, a toxicity profile consisting in neutropenia and fatigue, and early hints of an...

NRF2 as an Emerging Therapeutic Target

1MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 3GE, UK 2Division of Cancer Research, School of Medicine, University of Dundee, Dundee DD1 9SY, UK 3Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA 4Department of Pharmacology and Toxicology, Michigan State University...

dual-target anticancer drug candidates: rational design and simulation studies

this study aims to design some dual-target anticancer candidates, capable to act as an alkylating agent as well as a thymidylate synthase (ts) inhibitor. the designed scaffold is a combination of nucleobase, amino acid and aziridine structures. the candidates are docked into ts and three dna double strand structures and evaluated based on their binding interaction energies and ligand efficienci...